T cell receptors targeting TP53 hotspot mutations and uses thereof

WO2025024648A3PCT designated stage expired Publication Date: 2025-05-08MEMORIAL SLOAN KETTERING CANCER CENT +2
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/039524
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-25
Filing Date
2024-07-25
Publication Date
2025-05-08

AI Technical Summary

Technical Problem

Current cancer therapies lack effective strategies to target TP53 mutations, which are prevalent in over 40% of human cancers, without causing toxicity to normal tissues.

Method used

Development of novel recombinant T cell receptors (TCRs) that specifically target TP53 peptides with mutations, such as the R175H mutation, allowing for precise cancer cell eradication.

Benefits of technology

The recombinant TCRs effectively bind to TP53 mutant peptides, enabling targeted immunotherapy that selectively kills cancer cells with minimal risk of harming normal tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024039524_08052025_PF_FP_ABST
    Figure US2024039524_08052025_PF_FP_ABST
Patent Text Reader

Abstract

Provided and featured are novel recombinant T cell receptors (TCRs) that target a mutated tumor suppressor TP53. Also provided are cells comprising such TCRs, and methods of using the recombinant TCRs and cells expressing the recombinant TCRs for treating cancers associated with mutated TP53.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Tumor specific t-cell receptors

    US20150307585A1

  • High affinity t cell receptors and uses thereof

    US20180369280A1

  • T cell receptors recognizing mutated p53

    US20200277352A1

  • Novel t cell receptors and immune therapy using the same

    WO2018104478A1

  • Methods, kits, and approaches for viral vaccines

    WO2022216895A1